Medpace Holdings (MEDP) Income from Continuing Operations (2015 - 2026)
Medpace Holdings' (MEDP) quarterly Income from Continuing Operations came in at $121.4 million in Q2 2026, up 34.46% on a YoY basis from $90.3 million in Q2 2025, and down 2.02% quarter-over-quarter from $123.9 million in Q1 2026.
Analysis
Medpace Holdings (MEDP) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Medpace Holdings (MEDP) has reported Income from Continuing Operations for 12 consecutive years, with $121.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income from Continuing Operations rose 34.46% year-over-year to $121.4 million; the trailing twelve-month figure through Jun 2026 stood at $491.5 million (up 17.5% YoY), and the FY2025 full-year result was $451.1 million, up 11.56% from the prior year.
- Income from Continuing Operations retreated to $121.4 million in Q2 2026 per MEDP's latest filing, from $123.9 million in the prior quarter.
- Across five years, Income from Continuing Operations topped out at $135.1 million in Q4 2025 and bottomed at $49.4 million in Q2 2022.
- Historically, Income from Continuing Operations has averaged $90.5 million across 5 years, with a median of $89.3 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations soared 49.45% in 2024, then gained 2.16% in 2025.
- Over 5 years, Income from Continuing Operations stood at $68.7 million in 2022, then increased by 14.02% to $78.3 million in 2023, then jumped by 49.45% to $117.0 million in 2024, then gained by 15.48% to $135.1 million in 2025, then decreased by 10.19% to $121.4 million in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered $121.4 million, $123.9 million, and $135.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 241.00 Mn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | 121.36 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | 111.81 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | -760,000.00 |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | -13.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | -57.32 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | -426,000.00 |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | -4.28 Bn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | -2.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 121.36 Mn |
| Mar 31, 2026 | 123.87 Mn |
| Dec 31, 2025 | 135.13 Mn |
| Sep 30, 2025 | 111.14 Mn |
| Jun 30, 2025 | 90.26 Mn |
| Mar 31, 2025 | 114.60 Mn |
| Dec 31, 2024 | 117.02 Mn |
| Sep 30, 2024 | 96.43 Mn |
| Jun 30, 2024 | 88.35 Mn |
| Mar 31, 2024 | 102.59 Mn |
| Dec 31, 2023 | 78.30 Mn |
| Sep 30, 2023 | 70.55 Mn |
| Jun 30, 2023 | 61.07 Mn |
| Mar 31, 2023 | 72.89 Mn |
| Dec 31, 2022 | 68.67 Mn |
| Sep 30, 2022 | 66.03 Mn |
| Jun 30, 2022 | 49.36 Mn |
| Mar 31, 2022 | 61.31 Mn |
| Dec 31, 2021 | 50.03 Mn |
| Sep 30, 2021 | 48.57 Mn |